BN Business News
Add your company to Business Communicator →

Business · 15/09/2026Updated: 10/17/2026 · 1 min read

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

Summary

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →